Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indaptus Therapeutics’ pioneering work in bacterial immunotherapy makes its SEC disclosures unusually technical. Parsing a 10-K to locate R&D outlays for the Decoy20 program or scanning Form 4s for executive stock moves can consume hours—even for seasoned biotech analysts.
Stock Titan eliminates that burden with AI-powered summaries that translate dense language into plain English. Real-time alerts surface every Indaptus Therapeutics insider trading Form 4 transactions the moment they reach EDGAR, while interactive charts map option grants to clinical milestones. Looking for dilution clauses? Our engine flags the exact page in the Indaptus Therapeutics annual report 10-K simplified. Need the latest Indaptus Therapeutics quarterly earnings report 10-Q filing? One click reveals cash-runway metrics, trial timelines, and manufacturing updates—already annotated by AI.
Beyond the staples, you’ll also find:
- Indaptus Therapeutics 8-K material events explained within minutes of release
- Indaptus Therapeutics proxy statement executive compensation tables with peer benchmarks
- understanding Indaptus Therapeutics SEC documents with AI through concise highlight reels
- Indaptus Therapeutics earnings report filing analysis tracking burn-rate trends quarter over quarter
- Indaptus Therapeutics Form 4 insider transactions real-time push notifications
Whether you’re researching how bacterial immunotherapy platforms influence revenue projections or simply asking, “Where can I find Indaptus Therapeutics’ 10-K?”, our comprehensive coverage turns complex biotech filings into actionable insight. Stop wading through jargon—see the story behind each disclosure in minutes.
Indaptus Therapeutics (Nasdaq: INDP) filed an 8-K disclosing that its board executed a 1-for-28 reverse stock split of issued and outstanding common shares.
The Certificate of Amendment was filed in Delaware on 26 June 2025 and became effective at 5:00 p.m. ET. Split-adjusted trading begins 27 June 2025. Every twenty-eight shares automatically converted into one; no change to the $0.01 par value.
- No fractional shares: holders receive cash based on the 26 June Nasdaq closing price.
- All outstanding options and warrants were proportionally adjusted.
- Post-split shares continue to trade under ticker INDP; new CUSIP: 45339J 204.
- VStock Transfer, LLC will serve as exchange agent.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) has called a Special Meeting of Stockholders for July 25, 2025 at 10:00 a.m. Eastern Time at its New York headquarters. The record date is June 16, 2025, with 16,034,444 common shares outstanding and entitled to one vote each. The Board is soliciting proxies through this DEF 14A to obtain shareholder approval for two key proposals tied to an ongoing Rule 506(c) private placement of convertible notes and warrants.
- Issuance Proposal (Nasdaq Rule 5635(d)): Authorizes the issuance of common stock upon (i) conversion of the private-placement convertible notes and (ii) exercise of a series of warrants (common, pre-funded and placement-agent) arising from the same financing.
- Related-Party Proposal (Nasdaq Rule 5635(c)): Approves the issuance of common stock to the Company’s Chief Executive Officer and Director upon conversion of any such notes and upon exercise of related warrants that may be allotted to him.
Approval is required to comply with Nasdaq’s shareholder-approval rules because (i) the aggregate share issuance could exceed 20% of outstanding equity (Rule 5635(d)) and (ii) a director/CEO is a potential investor in the financing (Rule 5635(c)). Shareholders may vote by telephone, Internet, mail or in person; proxies are revocable, and in-person voting is permitted even after a proxy is submitted. Attendees must pre-register with building security and present photo ID; the Company may shift to a virtual format via a future Form 8-K if necessary.
Aside from routine matters and potential adjournments, no further business is scheduled. The Board recommends shareholders vote FOR each proposal.
Indaptus Therapeutics, Inc. (CIK 0001857044) filed a Form D notice with the SEC to report a new exempt offering of securities. The biotechnology company, incorporated in Delaware in 2021 and operating from 3 Columbus Circle, New York, is claiming the Rule 506(c) exemption, which allows general solicitation provided that all purchasers are accredited investors.
Offering details:
- Date of first sale: 12 June 2025
- Securities offered: (i) Options, warrants, or other rights to acquire another security and (ii) the underlying securities issuable upon exercise of those rights
- Minimum investment: $0 USD, indicating flexibility for investor entry size
- Offering duration: The issuer does not expect the offering to last more than one year
- Issuer size: The company elected “Decline to Disclose” for both revenue and asset ranges
Intermediary & solicitation: Paulson Investment Company, LLC (CRD 000005670) is identified as the broker-dealer. Solicitation will occur in multiple U.S. states (e.g., CA, CO, FL) and in foreign jurisdictions.
Management & directors: The filing lists key executives and directors, including CEO Jeffrey A. Meckler, CFO Nir Sassi, and several directors such as Roger J. Pomerantz and Hila Karah. No promoters are designated.
Other disclosures: • The offering is not tied to a business-combination transaction.
• No sales compensation recipients beyond Paulson Investment Company are disclosed.
• The issuer is categorised under the “Pharmaceuticals” industry segment.
Information gaps: Items concerning total amount offered, sold, and remaining are not present in the excerpt, limiting visibility into potential dilution and capital inflow.
FAQ
What is the current stock price of Indaptus Therapeutics (INDP)?
What is the market cap of Indaptus Therapeutics (INDP)?
What is the primary focus of Indaptus Therapeutics Inc?
How does the company's proprietary technology work?
What distinguishes Decoy20 from other immunotherapy candidates?
In what therapeutic areas is Indaptus Therapeutics active?
How does the technology address tumor immune evasion?
What role do strategic partnerships play for the company?
How does Indaptus ensure the safety of its immunotherapy candidates?
How does the company position itself in the competitive immunotherapy landscape?
